Text Size: A A A      Contrast:        Transparency in Coverage Rule

Retina Associates of Cleveland involved in "Avastin vs Lucentis" Study

Lawrence J. Singerman, MD of Retina Associates of Cleveland was a Principal Investigator for the CATT (Comparison of Age-related Macular Degeneration Treatments Trials) Study.  Results from this study were just released last night by the New England Journal of Medicine and showed that a much less expensive drug, Avastin, is as effective as the more expensive drug, Lucentis, for treating age-related macular degeneration (AMD), a leading cause of vision loss and blindness among the elderly.

Retina Associates of Cleveland (RACI) was recognized at a Chicago CATT Study meeting on April 26th as a “Center of Excellence” for their 95% follow-up success with Study patients  only 9 centers out of 44 worldwide achieved this recognition. One other center in Ohio enrolled patients in the CATT Study, Ohio State University.

RACI was the lead recruiter in the world for the clinical trials that led to FDA approval of Macugen, the first drug treatment available for macular degeneration. Lucentis and Avastin are similar drugs that subsequently proved to be more effective than Macugen. Retina Associates of Cleveland has done more randomized clinical trials in retina, including more NIH sponsored studies in retina than any other medical practice in the state of Ohio. Dr. Singerman has been a principal investigator for over 75 clinical studies.

View a copy of the official NIH/NEI press release here.